EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control

Quynh Nguyen iD, Martin Posch iD, Benjamin Hofner iD, Franz König iD

Pharmaceutical Statistics · 2026-07 · 25 (4)

DOI: 10.1002/pst.70106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 25.06.2026. Verfasst von Quynh Nguyen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section Data Science and Methods, Paul-Ehrlich-Institut, Langen, Germany. Hauptthemen laut MEDLINE: Research Design, Endpoint Determination, Clinical Trials as Topic. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platform trials evaluate multiple treatments within a single trial infrastructure. Such designs have gained a lot of attraction in clinical research. If information gained from platform trials should provide confirmatory evidence for regulatory decisions, control of the Type I error rate is key. One critical issue is information leakage, for example, if any information of the ongoing trial is available, especially if it may impact the further conduct of treatments still in the platform trial and bias their results. This paper evaluates the potential impact of information leakage on the control of the Type I error rate in platform trials with time‐to‐event endpoints such as overall survival. We explore different strategies how information on the treatment effect of an still ongoing treatment could be obtained if a pre‐planned analysis for another arm is conducted. This (leaked) information might be used to decide whether to continue the other arm as planned or conduct its final analysis immediately. By means of clinical trial simulations we evaluate the impact of different levels of information leakage on the Type I error rate. We show how the conditional error principle can be applied to estimate worst case Type I error rate inflation for the different forms of information leakage. We do not aim to quantify the exact maximum Type I error rate inflation but rather to raise awareness of the potential risk for estimation of comparative results. Finally, we discuss the regulatory implications of information leakage and propose strategies to mitigate these risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignEndpoint DeterminationClinical Trials as TopicHumansComputer SimulationBiasData Interpretation, StatisticalSurvival Analysis

Stichwörter der Autor:innen

common control groupconditional errormaximum Type I errortime‐to‐event

Autor:innen und Institutionen

  • Section Data Science and Methods, Paul-Ehrlich-Institut, Langen, Germany.
  • Department of Medical Informatics, Biometry, and Epidemiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, Austria.

ORCID-Profile: Quynh Nguyen, Martin Posch, Benjamin Hofner, Franz König

Zitieren

APA

Nguyen, Q., Posch, M., Hofner, B., & König, F. (2026). Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control. Pharmaceutical Statistics, 25(4). https://doi.org/10.1002/pst.70106

Vancouver

Nguyen Q, Posch M, Hofner B, König F. Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control. Pharmaceutical Statistics. 2026;25(4). doi:10.1002/pst.70106

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Quynh and Posch, Martin and Hofner, Benjamin and König, Franz},
  title = {Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {4},
  doi = {10.1002/pst.70106}
}
Kostenlos starten →